Pure Biologics begins in vivo research in the PB004 project

Polish biopharmaceutical company developing biological drugs and extracorporeal therapies based on antibodies and aptamers, Pure Biologics, announced it has signed a research agreement with The Jackson Laboratory (JAX), a leading American company providing animal research services around the world, to launch the first pilot in vivo preclinical study in the PB004 project, which aims to develop a drug candidate immunotherapeutic antibody for oncology applications.